Evidence map›Paper›PMID 38978848›Full record

ArticleActa medica Lituanic2024

Manifestations Reported by Inflammatory Bowel Disease Patients in University Hospital.

Ieva Renata Jonaitytė, Vita Karpavičiūtė, Gediminas Kiudelis, Juozas Kupčinska, Laimas Jonaitis

Abstract read
In one paragraph

Article in Acta medica Lituanic, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ieva Renata JonaitytėDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID https://orcid.org/0009-0002-5541-5089
Vita KarpavičiūtėDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID https://orcid.org/0009-0009-2513
Gediminas KiudelisDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID https://orcid.org/0000-0001-5945-8284
Juozas KupčinskaDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID https://orcid.org/0000-0002-8760-7416
Laimas JonaitisDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID https://orcid.org/0000-0001-9086-3675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory bowel disease (IBD) may affect organs outside the intestines, it is called extraintestinal manifestations of IBD. Data on the prevalence of mu-cocutaneous manifestations in IBD patients are very limited, therefore, the aim of this study was to assess the prevalence of skin and mucosal lesions and to determine the relationship with demographic factors, clinical features, and systemic treatment. Materials and methods: Prospective study included 162 out-patients with IBD who were managed in the tertiary care center. Ulcerative colitis (UC) was diagnosed in 117 patients, Crohn's disease (CD) in 45. Patients completed the questionnaire containing demographic and IBD data, questions about mucocutaneous lesions (in past or present state). Results: Overall mucocutaneous lesions were reported by 48.1% of IBD patients. Skin lesions were reported by 40.7% of patients, oral mucosal lesions were reported by 16.7%, without significant differences between sexes or IBD types. In 47 (29%) of patients, skin lesions appeared together with IBD or during the course of the disease. The most common skin lesions were psoriasis (8.0%), erythema nodosum (5.6%), pyoderma gangrenosum and acne (3.7% each). UC patients mostly reported about psoriasis (9.4%), while CD patients about erythema nodosum (11.1%). There were more frequent skin lesions in patients with more extensive UC type (p = 0.01), while no difference was noticed between different types of CD. The average duration of IBD in patients with skin lesions was similar to those without lesions (9.3±6.7 vs. 9.4±6.7 years). Conclusions: Mucocutaneous lesions were reported by 48.1% of inflammatory bowel disease patients. The frequency of mucocutaneous lesions does not differ significantly between UC and CD, and a longer duration of illness is not a predictive factor for the appearance of lesions. More extensive UC is related to higher frequency of skin lesions.

Indexed as

Crohn’s diseaseextraintestinal manifestationmucocutaneous lesionsskin lesionsulcerative colitis

Identifiers

PMID38978848
PMCPMC11227669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.